RXRXライブシグナル | Getagraph.comで利益を最大化

売る 4133 min ago

@ $8.06

発行日: 27 4月 2024 @ 04:51

リターン: 4.40%

前回のシグナル: 4月 27 - 03:19

前回のシグナル: 買う

リターン: 0.94 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):

Stats
本日の出来高	2.29M
平均出来高	6.38M
時価総額	1.94B
EPS	$0 ( 2024-02-26 )
次の収益日	( $-0.430 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.33
ATR14	$0.385 (4.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Khan Najat	Buy	0
2024-04-16	Borgeson Blake	Sell	11 447	Class A Common Stock
2024-04-17	Secora Michael	Buy	37 500	Class A Common Stock
2024-04-16	Secora Michael	Buy	37 500	Class A Common Stock
2024-04-17	Secora Michael	Sell	23 124	Class A Common Stock

INSIDER POWER
39.70
Last 99 transactions
Buy: 2 818 975 \| Sell: 1 171 582

ボリューム相関

長: 0.05 (neutral)

短: -0.32 (neutral)

Signal:(44) Neutral

Recursion 相関

10 最も正の相関
PLXP	0.893
LUMO	0.879
VIRX	0.876
FATE	0.874
STRC	0.867
HOOK	0.859
GROM	0.859
CLEU	0.857
SNCE	0.851
QTEK	0.85

10 最も負の相関
XOMAO	-0.832
CCRC	-0.827
XOMAP	-0.825
LUNA	-0.824
ITMR	-0.821
LRFC	-0.821
ACAHU	-0.814
AVEO	-0.813
MICT	-0.813
BNIXU	-0.811

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Recursion 相関 - 通貨/商品

-0.16
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.01
( neutral )

-0.65
( moderate negative )

0.07
( neutral )

Recursion 財務諸表

Annual	2023
収益:	$44.58M
総利益:	$-6.51M (-14.61 %)
EPS:	$-1.580

FY	2023
収益:	$44.58M
総利益:	$-6.51M (-14.61 %)
EPS:	$-1.580

FY	2022
収益:	$39.68M
総利益:	$-8.59M (-21.66 %)
EPS:	$-1.360

FY	2021
収益:	$10.18M
総利益:	$0.00 (0.00 %)
EPS:	$-1.658

Financial Reports:

No articles found.

Recursion

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.